Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2025-04-17 DOI:10.1111/1759-7714.15338

Zi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, John Wen-Cheng Chang, Chen-Te Wu, Chen-Yang Huang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Chiao-En Wu

{"title":"Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.","authors":"Zi-Ting Chang, Ping-Chih Hsu, How-Wen Ko, John Wen-Cheng Chang, Chen-Te Wu, Chen-Yang Huang, Ching-Fu Chang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Chiao-En Wu","doi":"10.1111/1759-7714.15338","DOIUrl":null,"url":null,"abstract":"Background: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte-to-lymphocyte ratio [MLR], and platelet-to-lymphocyte ratio [PLR]) and the treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with afatinib.Methods: The patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression-free survival [PFS] and tumor response) were explored using univariate and multivariate analyses.Results: Among 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by <18.8% had significantly better PFS. After adjusting for performance status, stage, and liver metastasis, the PFS was significantly unfavorable for an NLR decrease of <29.5% and MLR decrease of <57.9%. Among the patients with tumor response, NLR, MLR, and PLR significantly decreased after treatment (all p < 0.05).Conclusions: Our study presented the NLR, MLR, and PLR as prognostic factors for patients with NSCLC treated with afatinib. Further investigation into these markers representing the tumor microenvironment and their association with cancer status is crucial for evaluating prognosis and clinical outcomes in patients with NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15338","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte-to-lymphocyte ratio [MLR], and platelet-to-lymphocyte ratio [PLR]) and the treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with afatinib.

Methods: The patients with NSCLC treated with afatinib between June 2014 and February 2018 were retrospectively reviewed. Their inflammatory biomarkers and clinical outcomes (progression-free survival [PFS] and tumor response) were explored using univariate and multivariate analyses.

Results: Among 325 patients, those with an NLR >2.18, MLR >0.19, and PLR >177.73 had significantly worse PFS than those with lower values. After adjusting for performance status, stage, and liver metastasis, the PFS was still unfavorable for a baseline NLR >2.18, MLR >0.19, or PLR > 177.73. Among 188 patients with paired inflammatory values, those whose NLR decreased by >29.5%, MLR decreased by >57.9%, and PLR increased by <18.8% had significantly better PFS. After adjusting for performance status, stage, and liver metastasis, the PFS was significantly unfavorable for an NLR decrease of <29.5% and MLR decrease of <57.9%. Among the patients with tumor response, NLR, MLR, and PLR significantly decreased after treatment (all p < 0.05).

Conclusions: Our study presented the NLR, MLR, and PLR as prognostic factors for patients with NSCLC treated with afatinib. Further investigation into these markers representing the tumor microenvironment and their association with cancer status is crucial for evaluating prognosis and clinical outcomes in patients with NSCLC.

查看原文本刊更多论文

接受阿法替尼治疗的egfr突变NSCLC患者的基线和炎症参数的变化

背景：本研究探讨炎症生物标志物（淋巴细胞比率[NLR]、单核细胞与淋巴细胞比率[MLR]、血小板与淋巴细胞比率[PLR]）与阿法替尼治疗非小细胞肺癌（NSCLC）患者治疗结果的关系。方法：回顾性分析2014年6月至2018年2月期间接受阿法替尼治疗的非小细胞肺癌患者。他们的炎症生物标志物和临床结果（无进展生存期[PFS]和肿瘤反应）通过单因素和多因素分析进行了探讨。结果：325例患者中，NLR为2.18，MLR为0.19，PLR为177.73的患者PFS明显差于低值患者。在调整了表现状态、分期和肝转移后，基线NLR为2.18，MLR为0.19，PLR为177.73，PFS仍然不利。在188例具有配对炎症值的患者中，NLR降低了29.5%，MLR降低了57.9%，PLR增加了。结论：我们的研究表明NLR、MLR和PLR是阿法替尼治疗的非小细胞肺癌患者的预后因素。进一步研究这些代表肿瘤微环境的标志物及其与癌症状态的关联，对于评估非小细胞肺癌患者的预后和临床结果至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.